<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04205565</url>
  </required_header>
  <id_info>
    <org_study_id>PHMS201614F</org_study_id>
    <nct_id>NCT04205565</nct_id>
  </id_info>
  <brief_title>Study on Clinical Effectiveness of L-Oxiracetam Injection</brief_title>
  <official_title>A Randomized, Double-blind, Positive Drug/Placebo Parallel Controlled, Multicenter, Phase II Exploratory Clinical Trial of L-oxiracetam Injection to Improve Memory and Cognitive Impairment in Patients With Craniocerebral Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Yoko Biomedical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Yoko Biomedical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, positive drug/placebo parallel controlled, multicenter, phase II&#xD;
      exploratory clinical trial of L-oxiracetam injection to improve memory and cognitive&#xD;
      Impairment in patients with craniocerebral injury.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 8, 2017</start_date>
  <completion_date type="Actual">January 3, 2020</completion_date>
  <primary_completion_date type="Actual">January 3, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference of Loewenstein Occupational Therapy Cognitive Assessment (LOCTA) scores between baseline and 3 months after administration of drugs.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Craniocerebral Injury</condition>
  <arm_group>
    <arm_group_label>L-oxiracetam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxiracetam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Plaecbo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose group: L-oxiracetam Injection</intervention_name>
    <description>L-oxiracetam injection, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.</description>
    <arm_group_label>L-oxiracetam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose group: L-oxiracetam Injection</intervention_name>
    <description>L-oxiracetam injection, 3 vials, once a day, IV. Placebo injection of l-oxiracetam, 1 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.</description>
    <arm_group_label>L-oxiracetam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control group: Oxiracetam Injection</intervention_name>
    <description>Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Oxiracetam injection, 6 vials, once a day, IV.</description>
    <arm_group_label>Oxiracetam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo group: Placebo Injection</intervention_name>
    <description>Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.</description>
    <arm_group_label>Plaecbo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-75 years old (including upper and lower limits), male or female&#xD;
&#xD;
          2. Craniocerebral injury meets all of the following conditions: This diagnosis has a&#xD;
             clear head trauma, closed head injury, or head injury with cerebrospinal fluid ear&#xD;
             leak and / or nasal leak and / or intracranial gas accumulation; MRI or CT confirmed&#xD;
             intracranial hemorrhage above the cerebellum (including cerebral contusion,&#xD;
             subarachnoid hemorrhage, epidural hematoma, subdural hemorrhage, intracranial&#xD;
             hematoma, etc.), with or without transient coma; Craniocerebral injury is classified&#xD;
             as mild or moderate (GCS score 10-15 points); Conservative treatment.&#xD;
&#xD;
          3. Within 72 hours after head injury, patients with stable and mentally handicapped&#xD;
             mental state examination (MMSE) scores are lower than normal.&#xD;
&#xD;
          4. The legal representative and / or patient agree to participate in this clinical trial&#xD;
             and sign an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. People who are known or suspected to be allergic to the test drug and its ingredients.&#xD;
&#xD;
          2. After the injury, drugs that improve cognitive function such as the prohibited drugs&#xD;
             listed in the protocol have been used.&#xD;
&#xD;
          3. With a history of severe traumatic brain injury, a history of cerebrovascular&#xD;
             accidents, and structural craniocerebral lesions.&#xD;
&#xD;
          4. With diseases such as speech and hearing impairment that cannot cooperate with the&#xD;
             completion of cognitive function assessment.&#xD;
&#xD;
          5. A secondary brain injury occurred after the craniocerebral injury.&#xD;
&#xD;
          6. Those who need craniotomy or extraventricular drainage.&#xD;
&#xD;
          7. Combining with other serious large organ damage or serious complications may affect&#xD;
             the test Life.&#xD;
&#xD;
          8. Patients with active epilepsy who had seizures within 1 year.&#xD;
&#xD;
          9. Patients with severe liver and kidney disease.&#xD;
&#xD;
         10. Complicated with severe heart disease, lung disease, blood and hematopoietic diseases,&#xD;
             gastrointestinal disease, serious or progressive disease.&#xD;
&#xD;
         11. Past or present with a malignant tumor&#xD;
&#xD;
         12. Combining neurological and mental disorders that make it impossible or unwilling to&#xD;
             cooperate.&#xD;
&#xD;
         13. Women who are pregnant, breastfeeding or have a recent birth plan.&#xD;
&#xD;
         14. Researchers do not consider it appropriate to participate in the clinical trial.&#xD;
&#xD;
         15. Those who have participated in other clinical trials and used test drugs 3 months&#xD;
             before the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>General Hospital of Tianjin Medical University</name>
      <address>
        <city>Tianjing</city>
        <state>Tianjing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>L-oxiracetam</keyword>
  <keyword>Cognitive Impairment</keyword>
  <keyword>Craniocerebral Injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Craniocerebral Trauma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxiracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

